Axogen, Inc. AXGN
56.35 USD -0.60 (-1.05%)
Regular-session close
56.35 0.00 0.00%
After hours · Nov 19, 4:17 PM ET
56.06 Day range 58.35
25.16 52-week range 59.72
- YTD
- +72.17%
- 1 year
- +123.08%
News
benzinga.com Leerink Partners Maintains Outperform on Axogen, Raises Price Target to $65 Leerink Partners analyst Mike Kratky maintains Axogen (NASDAQ:AXGN) with a Outperform and raises the price target from $56 to $65.
fool.com AxoGen: 3 Key Takeaways for Long-Term Investors AxoGen raised full-year 2026 revenue guidance to at least $290 million. Commercial payer coverage for Avance reached 96% of covered U.S. lives.
zacks.com AxoGen (AXGN) is a Great Momentum Stock: Should You Buy? Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
seekingalpha.com Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript
globenewswire.com Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of…
zacks.com GMED vs. AXGN: Which Stock Should Value Investors Buy Now? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for…
seekingalpha.com Axogen: Taking The Friction Out Of Nerve Repair Axogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next decade. Q3 2026 saw 26% revenue growth, 45%…benzinga.com Canaccord Genuity Maintains Buy on Axogen, Raises Price Target to $60 Canaccord Genuity analyst Caitlin Roberts maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $55 to $60.
benzinga.com Leerink Partners Maintains Outperform on Axogen, Raises Price Target to $56 Leerink Partners analyst Mike Kratky maintains Axogen (NASDAQ:AXGN) with a Outperform and raises the price target from $52 to $56.
benzinga.com Barclays Maintains Overweight on Axogen, Raises Price Target to $60 Barclays analyst Christopher Pasquale maintains Axogen (NASDAQ:AXGN) with a Overweight and raises the price target from $50 to $60.
zacks.com Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year? Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.benzinga.com Truist Securities Maintains Buy on Axogen, Raises Price Target to $60 Truist Securities analyst Ravi Misra maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $53 to $60.
benzinga.com Wells Fargo Maintains Overweight on Axogen, Raises Price Target to $56 Wells Fargo analyst Larry Biegelsen maintains Axogen (NASDAQ:AXGN) with a Overweight and raises the price target from $48 to $56.
benzinga.com Microsoft To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for Microsoft, VF, Glaukos, Hilton, AxoGen and Brinker; Renasant’s target was cut and its rating downgraded.benzinga.com HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $56 HC Wainwright & Co. analyst Yi Chen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $53 to $56.
marketbeat.com AxoGen Q3 Earnings Call Highlights AxoGen NASDAQ: AXGN reported third-quarter revenue growth of 26.2% as demand for its nerve-repair products increased across its breast, extremities, oral and maxillofacial, and head-and-neck markets.…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com Crude Oil Surges Over 3%; Brinker Posts Upbeat Earnings U.S. stocks were mixed; Dow and S&P 500 rose while Nasdaq slipped. Brinker beat estimates and raised guidance; oil jumped 3.4%.
seekingalpha.com Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript
benzinga.com Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance; Ultralife soared 145.8% on buyout news.
zacks.com AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates AxoGen (AXGN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.
benzinga.com Axogen Q3 2026 Earnings Call Transcript Axogen (NASDAQ:AXGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…benzinga.com Axogen Q3 Adj. EPS $0.21 Beats $0.14 Estimate, Sales $75.834M Beat $73.199M Estimate Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.14 by 50 percent. This is a 75 percent increase over earnings of $0.12 per share…
globenewswire.com Axogen, Inc. Reports Third Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million Raises Full Year Revenue Guidance to at Least 29% Growth or $290 millionbenzinga.com Barclays Maintains Overweight on Axogen, Lowers Price Target to $50 Barclays analyst Christopher Pasquale maintains Axogen (NASDAQ:AXGN) with a Overweight and lowers the price target from $55 to $50.
zacks.com AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com GMED or AXGN: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better…
globenewswire.com Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026 ALACHUA, Fla. and TAMPA, Fla.
zacks.com Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN) The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in…
prnewswire.com Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week /PRNewswire/ -- Stock Preachers News Commentary - Big technology names pulled the Nasdaq Composite to a weekly gain while the Dow Jones Industrial Average and
globenewswire.com Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair ALACHUA, Fla. and TAMPA, Fla.
gurufocus.com Axogen Inc (AXGN) Shares Fall 3.0% -- GF Value Says Still Overvalued On September 22, 2026, Axogen Inc (AXGN) shares fell by 3.0%, closing at $44.54. The stock is currently trading within a 52-week range of $15.27 to $52.91.
benzinga.com Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.
schaeffersresearch.com 2 Medical-Device Stocks Lighting Up the Options Pits Medical-device stocks Cooper Companies Inc (NASDAQ:COO) and Axogen Inc (NASDAQ:AXGN) are both sharply lower following separate company developments, and options traders are chiming in.
